Anorexia Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)

DelveInsight's, "Anorexia Pipeline Insight, 2023," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Anorexia pipeline landscape. It covers the Anorexia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Anorexia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Anorexia Pipeline Report
• DelveInsight's Anorexia pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Anorexia treatment.
• The leading companies working in the Anorexia Market include Amgen, COMPASS Pathways, Benuvia Therapeutics, Artelo Biosciences, RaQualia Pharma, Receptor Life Sciences, Pfizer, and others.
• Promising Anorexia Pipeline Therapies in the various stages of development include RM-131, Psilocybin, Ketamine Hcl 50Mg/Ml Inj, olanzapine, Megestrol acetate, Teriparatide, and others.
• October 2023: Karen Klahr Miller, MD announced a study of Phase 3 clinical trials for Romosozumab Prefilled Syringe and Alendronate 70Mg Tab. This protocol is a randomized, double-blind, placebo-controlled clinical trial which aims to investigate the effect of romosozumab on BMD in women with anorexia nervosa. The investigators will also investigate the safety of romosozumab in women with anorexia nervosa. The investigators hypothesize that 12 months of romosozumab administration will result in an increase in bone mineral density, increase in markers of bone formation and decrease in markers of bone resorption, and improvement in bone microarchitecture in osteopenic women with anorexia nervosa compared with placebo.
• October 2023: Pfizer announced a study of Phase 2 clinical trials for ponsegromab. Study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15.

Request a sample and discover the recent advances in Anorexia Treatment Drugs @ Anorexia Pipeline Report- https://www.delveinsight.com/report-store/anorexia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Anorexia pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Anorexia NDA approvals (if any), and product development activities comprising the technology, Anorexia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Anorexia Overview
Anorexia Nervosa is a serious eating disorder that is treatable but can be life-threatening without intervention. With over 200,000 individuals in the United States impacted per year and the highest mortality rate of any mental illness, it is important to learn the signs, symptoms, and treatment options for this disorder.

Find out more about Anorexia Therapeutics Assessment @ Anorexia Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/anorexia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Anorexia Emerging Drugs Profile
• ART2713: Artelo Biosciences

Anorexia Pipeline Therapeutics Assessment
There are approx. 5+ key companies which are developing the Anorexia therapies. The Anorexia companies which have their Anorexia drug candidates in the mid to advanced stage, i.e. Phase I/II include, Artelo Biosciences.

Anorexia Pipeline Segmentation
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Learn more about the emerging Anorexia Pipeline Therapies @ Anorexia Clinical Trials Assessment- https://www.delveinsight.com/sample-request/anorexia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Anorexia Pipeline Report
• Coverage- Global
• Anorexia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Anorexia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Anorexia Companies- Amgen, COMPASS Pathways, Benuvia Therapeutics, Artelo Biosciences, RaQualia Pharma, Receptor Life Sciences, Pfizer, and others.
• Anorexia Pipeline Therapies- RM-131, Psilocybin, Ketamine Hcl 50Mg/Ml Inj, olanzapine, Megestrol acetate, Teriparatide, and others.

Dive deep into rich insights for new drugs for Anorexia Treatment, Visit @ Anorexia Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/anorexia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Anorexia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Drug Name: Company Name
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase I/II)
10. ART2713: Artelo Biosciences
11. Drug profiles in the detailed report…..
12. Pre-clinical and Discovery Stage Products
13. RQ 00433412: RaQualia Pharma
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Anorexia Key Companies
17. Anorexia Key Products
18. Anorexia- Unmet Needs
19. Anorexia- Market Drivers and Barriers
20. Anorexia- Future Perspectives and Conclusion
21. Anorexia Analyst Views
22. Anorexia Key Companies
23. Appendix

For further information on the Anorexia Pipeline therapeutics, reach out to Anorexia Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/anorexia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking

This release was published on openPR.